

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16  
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2019

---

Commission File Number: 001-37891

**AC IMMUNE SA**

(Exact name of registrant as specified in its charter)

**EPFL Innovation Park  
Building B  
1015 Lausanne, Switzerland**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F                      X                      Form 40-F                      \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes                      \_\_\_\_\_                      No                      X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes                      \_\_\_\_\_                      No                      X

---

---

As previously disclosed in the report on Form 6-K furnished on December 12, 2018, AC Immune SA and Eli Lilly and Company entered into a license and collaboration agreement (the "License Agreement") subject to customary antitrust review. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired as of 11:59 p.m. EST on January 22, 2019. As a result, all conditions to effectiveness have been met and the License Agreement became effective as of January 23, 2019. For a description of the terms of the License Agreement, refer to the report on Form 6-K furnished on December 12, 2018.

This report on Form 6-K hereto shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration Number: 333-224694), the registration statement on Form F-3 (Registration Number: 333-227016) and the registration statement on Form S-8 (Registration Number: 333-216539) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**AC IMMUNE SA**

By: /s/ Andrea Pfeifer

Name: Andrea Pfeifer

Title: Chief Executive Officer

By: /s/ Joerg Hornstein

Name: Joerg Hornstein

Title: Chief Financial Officer

Date: January 23, 2019

---